NimBio, an early-stage company in the eHealth Ventures portfolio is happy to announce the initiation of a clinical study with its personalized remote care platform for immune-mediated-inflammatory diseases (IMIDs).
The clinical trial involves remote home monitoring, further enhancing the capabilities of NimBio’s solution. NimBio aims to prevent inflammatory flare ups, reduce patient readmissions and optimise therapy of IMIDs. NimBio is developing a non-invasive wearable device that provides continuous measurements of inflammatory biomarkers aiming to improve care, initially focusing on Inflammatory Bowel Diseases (IBD).
This important milestone is coupled with an investment by a European VC, Venturing Holding BV, which will enable adding additional sites to the study, expanding the team and strengthening the company’s IP.
Prof. Yehuda Chowers, co-founder and Chief Medical Officer of NimBio: “We are happy to start recruitment for this major trial, led by Prof. Iris Dotan, Director of the Division of Gastroenterology at the Rabin Medical Center, Israel. This will further validate our ground-breaking solution and provide a non-invasive disease management tool to an array of diseases consisting of a very large market with a strong unmet need”.
For more details: email@example.com
About eHealth Ventures
The eHealth Ventures partnership is a leading investor in early-stage digital health companies.
It includes 2 VC funds and a technological incubator with an exclusive focus on digital health and significant government non-dilutive funding. Partners include Maccabi (a leading Israeli HMO), Amgen (global biotech giant), the Mayo Clinic, Medison Ventures, Arad Investments, and the Hadar Group. The team has reviewed over 1,650 companies to date and invested in a portfolio of 24 highly innovative companies (digital diagnostics, therapeutics, home care and Bioconvergence).